Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm
NCT ID: NCT02947815
Last Updated: 2019-06-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
234 participants
INTERVENTIONAL
2016-10-31
2018-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Korean Botulinum Toxin Type A Versus Botox in the Treatment of Essential Blepharospasm
NCT00682760
Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm
NCT00761592
The Objective of This Study is to Evaluate the Efficacy and Safety of Botulax® in Patients With Essential Blepharospasm.
NCT03641950
Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus
NCT01584843
Efficacy and Safety Study of Meditoxin® to Treat Essential Blepharospasm
NCT01259557
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NABOTA
Single-dose
Clostridium Botulinum Toxin Type A
BOTOX
Single-dose
Clostridium Botulinum Toxin Type A
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Clostridium Botulinum Toxin Type A
Clostridium Botulinum Toxin Type A
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Grade 2\~4 in Scott's scale
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Daewoong Pharmaceutical Co. LTD.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the catholic university of korea, Seoul ST. Mary's Hospital.
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DW_DWP450007
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.